Earlier this year, MSK announced the formation of MSK Ventures, a dedicated venture capital fund which will enable MSK to systematically invest in and help develop, scale, and, in some instances, translate new discoveries and services while diversifying long-term revenue streams. Whitney Snider, MD, joined MSK as Inaugural Managing Partner, after most recently serving as Principle and Vice President of Life Sciences at Alexandria Venture Investments.
Two months into this new role, Dr. Snider spoke with our team about her plans, priorities, and early impressions.
Q: Tell us about your vision for MSK Ventures.
Dr. Snider: MSK Ventures represents the next evolution of MSKCC’s long-standing commitment to translating discovery into patient impact.
MSK has contributed to the FDA approval of more than 15 cancer therapies in the past five years alone. Many of the most consequential advances in modern oncology were conceived in MSK laboratories and validated in our clinics. For decades, this innovation engine has been supported by our licensing and business development experts. The Office of Entrepreneurship and Commercialization (OEC) executed nearly two hundred licensing agreements last year alone.
MSK Ventures builds on that foundation by institutionalizing venture investing as a core capability. We are designed to invest in high-conviction companies affiliated with MSK — whether built on MSK intellectual property, founded by MSK investigators, or strategically aligned with our scientific and clinical ecosystem.
Q: First and foremost, MSK is a globally renowned cancer center. Why branch out in this way?
Dr. Snider: Our mandate is dual and mission-aligned: First, to generate institutional-quality financial returns that strengthen MSK’s long-term sustainability. Second, to accelerate patient-impactful innovation.
By backing companies rooted in MSK science, data, and/or clinical insight, we can influence innovation at the point of origination, help shape durable platforms that endure or partner with more mature companies leveraging MSK technology or complementing work at MSK to accelerate development. Ultimately, success means more therapies reaching patients, more companies built on MSK science, and stronger long-term financial sustainability for the institution.
Q: Why take this step now?
Dr. Snider: Internally, institutionally, MSK has already demonstrated that disciplined, mission-aligned investing works. Over the past decade, MSK has invested in numerous companies founded on MSK science. Those investments have been very accretive with several companies achieving IPOs or strategic acquisitions. Juno Therapeutics’ growth and acquisition is a strong example of what’s possible when academic science and disciplined capital come together.
MSK Ventures formalizes and scales that strategy. It’s structured as a dedicated venture capital vehicle with independent governance, a Limited Partner framework, and rigorous underwriting processes. This creates a repeatable, scalable model aligned with MSK’s 2030 strategic vision, particularly the “EXPAND” pillar focused on innovation, growth, and sustainability.
Q: And from the external perspective?
Dr. Snider: Externally, the timing is compelling. We’re seeing extraordinary scientific progress across oncology, cell and gene therapy, radiopharmaceuticals, and AI-enabled platforms — yet capital markets remain constrained and valuations have reset. In that environment, disciplined, long-term investors with deep domain expertise have a structural advantage.
MSK is institutionally ready. Our commercialization ecosystem — including the Entrepreneurship Initiative, Tx Bridge Labs, the Therapeutics Accelerator, and iHub — has matured significantly. MSK Ventures is the next logical step in that evolution.
Q: You’re trained as a physician, you’re a Harvard MBA, and you have extensive experience in healthcare entrepreneurship and investment. What attracted you to this opportunity?
Dr. Snider: I’m honored to serve as the lead and Managing Partner of MSK’s inaugural venture capital fund. The role sits at the intersection of everything that has shaped my career and inspires me most: medicine, company formation, venture investing, capital allocation, strategy, and building enduring relationships. It is a rare opportunity to bring those threads together in service of a singular mission.
I’ve seen firsthand how transformative MSK science is —particularly in a company setting when paired with the right capitalization and experienced leadership. In my most recent role at Alexandria Venture Investments, I spent six and a half years sourcing investments across biotech and therapeutic platforms. I had the privilege of investing in several companies that emerged from the MSK ecosystem, which allowed me to develop deep relationships with the institution, its faculty, and the Office of Entrepreneurship and Commercialization.
Earlier in my career, while at Inning One Ventures, I co-led the formation of Ajax Therapeutics in close collaboration with MSK’s current CSO, Dr. Ross Levine. That experience was career-defining. It crystallized for me the power of pairing exceptional scientific leadership with the right capital strategy and a clear focus on patient need. Prior to that, at Celgene, I was part of the deal team for the $1B collaboration with Juno Therapeutics—a company founded on MSK intellectual property. Across each of these experiences, I saw how disciplined investment and thoughtful company building can accelerate the translation of breakthrough science into meaningful therapies.
MSK Ventures represents the opportunity to bring together my clinical training, investment rigor, and venture formation experience in one place—directly aligned with advancing patient impact at scale.
On a personal level, this work is deeply meaningful. Both of my parents have dedicated their careers to caring for patients and families affected by cancer at Dana-Farber Cancer Institute—my father as a physician-scientist and my mother in the General Counsel’s office. I’ve long admired their sense of purpose, resilience and commitment. To now contribute to an institution so profoundly committed to ending cancer for life is both humbling and deeply motivating.
Q: After two months at MSK Ventures, what’s surprised you? What are you most excited about? What are the challenges?
Dr. Snider: What has surprised me most is the sheer breadth of opportunity. The innovation pipeline spans therapeutics, platform technologies, diagnostics, radiopharmaceuticals, computational oncology, and AI applications that leverage MSK’s clinical and genomic data.
What excites me most is our ability to invest at the point of origination. We have access to proprietary science, early human data, and clinicians embedded in real-world care. That clinical validation capability is a true differentiator. It allows us to assess risk and potential with greater precision. I’m equally excited about the opportunity to invest in more mature companies, as well, with existing management teams and venture capital investments and syndicates – that leverage MSK’s IP or faculty expertise. There is a broad aperture for us to consider in diversifying our portfolio of investments and thinking thoughtfully about our distribution of risk – and future returns.
The challenge — and it’s a healthy one — is building a disciplined venture platform inside an academic medical center. That requires thoughtful governance, conflict-of-interest management, and a clear separation between clinical mission and capital allocation. We’ve built strong structures around an independent Investment Committee, advisory input from experienced external investors, and rigorous reporting to ensure accountability.
Q: Do you anticipate synergies with other initiatives or teams within MSK?
Dr. Snider: Absolutely. MSK Ventures is embedded within a broader innovation ecosystem.
We work closely with the Office of Entrepreneurship and Commercialization team, the Entrepreneurship Initiative, Tx Bridge Labs, the Therapeutics Accelerator, and iHUB. These programs generate, incubate, and de-risk ideas. MSK Ventures provides structured, dilutive capital to help scale the most compelling opportunities that have investments from other institutional investors and a management team in place.
A meaningful portion of my time that is spent internally is in engaging with faculty and existing projects — evaluating technologies, shaping strategy, and aligning around development pathways. The rest involves working with external investors, founders, and biopharma partners.
This role is inherently collaborative — both internally and externally.
Q: What are the opportunities for MSK Ventures within the NYC and regional biotech and investment communities?
Dr. Snider: New York has matured significantly as a life sciences hub. There’s increasing density of venture capital, biotechnology companies, and strategic partners.
MSK Ventures brings something uniquely differentiated to that ecosystem: direct access to world-leading oncology science and clinical insight. Our brand and scientific credibility help attract top-tier co-investors and founders. That convening power lowers friction in syndication and partnership formation.
We see real opportunity to build globally competitive companies rooted in MSK science while strengthening the regional innovation ecosystem.
Q: Can you share some of your goals for 2026? Further ahead, what will success look like?
Dr. Snider: In 2026, our priorities are to fully launch MSK Ventures Fund I — deploy capital thoughtfully across several high-conviction early-stage investments, and establish strong governance and reporting infrastructure.
Longer term, success will be measured on multiple dimensions.
Financially, we are targeting venture-standard performance metrics and disciplined portfolio construction.
Strategically, success means, over time, a growing percentage of our portfolio originating from MSK startups, meaningful downstream capital attracted, and clinical translation milestones achieved.
Most importantly, success means that breakthrough therapies and technologies rooted in MSK science reach patients — while strengthening the institution’s financial foundation for decades to come.
Q: Any final thoughts?
Dr. Snider: One question I often reflect on personally is what it truly takes to move an idea from lab bench to patient bedside.
Capital is essential — but it’s not sufficient. It takes mentorship, scientific rigor, translational infrastructure, disciplined governance, and long-term alignment.
MSK Ventures is designed to bring those elements together. We’re not just investing in companies — we’re helping build enduring platforms where science meets patients, and where innovation strengthens the institution that made it possible.
That’s the opportunity ahead of us.
For more about MSK Ventures, see here.